Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company focused on orthopedic treatments, is advancing its lead product GelrinC(R) through European commercialization and a U.S. pivotal clinical trial. Executive Chairman and CEO Dr. Ehud Geller provided updates on these efforts during a recent episode of The BioMedWire Podcast.
GelrinC(R) is a cell-free, off-the-shelf hydrogel implant designed to treat cartilage injuries in the knee. According to Geller, the product is already approved for marketing in Europe and is currently undergoing a U.S. pivotal clinical trial. Regentis is working to expand clinical sites and aims to complete patient enrollment around year-end. The company is also engaging with distribution systems and major orthopedic companies to advance European commercialization.
The potential impact of GelrinC(R) is significant. The U.S. market for cartilage knee repair involves approximately 470,000 cases annually where no off-the-shelf treatment is available. GelrinC(R) aims to address this unmet need by providing an accessible solution that regenerates damaged tissue. The hydrogel is based on Regentis’ Gelrin platform technology, which uses synchronized, degradable hydrogel implants to regenerate damaged or diseased tissue, including inflamed cartilage and bone. Once implanted, GelrinC(R) is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process.
For investors and industry observers, Regentis’ progress could signal a shift in the orthopedic treatment landscape. If the U.S. pivotal trial is successful, GelrinC(R) could become the first off-the-shelf treatment for cartilage knee repair in the United States, potentially capturing a substantial share of the 470,000 annual cases. The European commercialization efforts, if successful, would generate near-term revenue and validate the technology ahead of U.S. approval.
To view the full press release, visit https://ibn.fm/4Tu64. The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT.
This content has been disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid investor awareness and marketing engagement. For more information about BioMedWire, visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
